Pentoxifylline Treatment in Acute Pancreatitis (AP)

Participants were randomized to either the treatment group (Pentoxifylline medication) or the
control group (Placebo).

Participant took a pill orally, starting from the time of admission. Participants received a
total of 9 doses over the three days of hospitalization (72 hours).

Research blood draws were done at baseline and on 5 successive days or until the time of
discharge, whichever occured earlier. The study gathered clinical follow up information up to
4 months following hospitalization regarding the diagnosis of acute pancreatitis.

Inclusion criteria

- Enrollment within 72 hours of diagnosis of acute pancreatitis (AP)

- Ability to give informed consent or a Legal Adult Representative (LAR) able to give
informed consent for subject when needed as defined buy LAR use guidelines.

- Adult subjects of age ≥18 years.

Exclusion Criteria:

- Moderate or severe congestive heart failure

- History of seizure disorders or demyelinating disease

- Nursing mothers

- Pregnancy

- History of prior tuberculosis or risk factors for tuberculosis

- Evidence of non- corticosteroid immunosuppression (such as malignancy, chronic renal
failure, chemotherapy within 60 days, and HIV)

- Evidence of active hemorrhage

- Paralytic ileus with severe nausea and vomiting